Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.51 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.50 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.49 |
| ▸ | CCNC | P24863 | 1/20 | 0.49 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11034681 | 0.94 | TBXAS1 (0.60) | TBXAS1KMT2ACHRNB2CHRNA4CYSLTR2 | |
| SCHEMBL12480735 | 0.94 | TBXAS1 (0.60) | TBXAS1KMT2ACHRNB2CHRNA4CYSLTR2 | |
| SCHEMBL15426554 | 0.84 | KMT2A (0.54) | KMT2ACHRNB2CHRNA4CCNCCDK8 | |
| SCHEMBL6067800 | 0.84 | TSHR (0.58) | TBXAS1CHRNB2CHRNA4GRM2CCNC | |
| SCHEMBL7994994 | 0.82 | CYSLTR2 (0.54) | TBXAS1KMT2ACYSLTR2CYSLTR1FAAH | |
| SCHEMBL767042 | 0.82 | TDP1 (0.62) | CYSLTR2CYSLTR1FAAHLMNATSHR | |
| SCHEMBL15429530 | 0.79 | CHRNB2 (0.50) | KMT2ACHRNB2CHRNA4GRM2 | |
| SCHEMBL7892601 | 0.79 | NCOA1 (0.52) | KMT2ACHRNB2CHRNA4CCNCCDK8 | |
| SCHEMBL10622938 | 0.78 | TBXAS1 (0.57) | TBXAS1KMT2ATSHR | |
| SCHEMBL5491821 | 0.77 | LTA4H (0.62) | CYSLTR2CYSLTR1FAAHTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002395-A1 | AZABENZIMIDAZOLE COMPOUND AND MEDICINE | NIPPON SHINYAKU CO., LTD. (JP) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002395-A1 | AZABENZIMIDAZOLE COMPOUND AND MEDICINE | PAM, CHRM3, AZI2 | TBXAS1 3935/4885KMT2A 1035/4885CHRNB2 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.